Exscientia Holdings Limited (EXAI): Price and Financial Metrics
EXAI Price/Volume Stats
Current price | $5.72 | 52-week high | $9.12 |
Prev. close | $5.78 | 52-week low | $4.17 |
Day low | $5.65 | Volume | 504,600 |
Day high | $5.87 | Avg. volume | 749,457 |
50-day MA | $6.18 | Dividend yield | N/A |
200-day MA | $6.14 | Market Cap | 691.47M |
EXAI Stock Price Chart Interactive Chart >
Exscientia Holdings Limited (EXAI) Company Bio
Exscientia plc, an artificial intelligence-driven pharmatech company, engages in discovering, designing, and developing drugs. It offers end-to-end solution of artificial intelligence and technologies for target identification, drug candidate design, translational models, and patient selection. Its platform allows to design candidate drug molecules, as well as to provide patients with drug therapies through AI guided assessment. The company was founded in 2012 and is headquartered in Oxford, the United Kingdom.
Latest EXAI News From Around the Web
Below are the latest news stories about EXSCIENTIA PLC that investors may wish to consider to help them evaluate EXAI as an investment opportunity.
Wall Street Analysts See a 67.76% Upside in Exscientia PLC Sponsored ADR (EXAI): Can the Stock Really Move This High?The consensus price target hints at a 67.8% upside potential for Exscientia PLC Sponsored ADR (EXAI). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term. |
Exscientia Announces Expansion of its Current Collaboration with Sanofi to Include Existing Exscientia ProgrammeOXFORD, England, December 21, 2023--Exscientia plc (Nasdaq: EXAI) today announced that Sanofi is adding a new discovery stage programme identified and initially advanced by Exscientia into the current collaboration. In this programme, Exscientia has designed a novel lead series with a potential best in class profile, with preliminary data showing good potency and selectivity towards the target and differentiated molecular properties. |
Is DexCom (DXCM) Stock Outpacing Its Medical Peers This Year?Here is how DexCom (DXCM) and Exscientia PLC Sponsored ADR (EXAI) have performed compared to their sector so far this year. |
Looking for the Next Big Thing? Add This AI Biotech to Your Watch List Right NowExscientia (NASDAQ: EXAI) is one such business undertaking this effort, and it's worth adding to your watch list today. Much like the other biotech businesses hoping to use AI for drug development, Exscientia believes that its AI-based platform can shorten development timelines, reduce failure rates in pre-clinical and clinical trials, and lower costs for drug makers. Exscientia's flagship program is cancer treatment candidate GTAEXS617. |
Micro/Small Cap Companies Using AI In Drug Discovery Up 35% In NovemberThe AI method is up to 250 times more efficient than the traditional method of drug discovery. reducing timelines for drug discovery, increasing accuracy of efficacy and safety predictions. |
EXAI Price Returns
1-mo | -14.88% |
3-mo | -10.76% |
6-mo | 26.55% |
1-year | 7.92% |
3-year | N/A |
5-year | N/A |
YTD | -10.76% |
2023 | 20.26% |
2022 | -73.03% |
2021 | N/A |
2020 | N/A |
2019 | N/A |
Loading social stream, please wait...